RHBC
SGMO

R.H. Bluestein & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

R.H. Bluestein & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,600
Closed -$536K – 316
2018
Q3 		$536K Buy
+31,600
New +$480K 0.03% 151

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

R.H. Bluestein & Co's SGMO Position: Q4 2018 in Review

R.H. Bluestein & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2018, closing a stake of 31,600 shares — an estimated $536K sold.

R.H. Bluestein & Co first reported a position in SGMO in Q3 2018 and held it in 1 quarter. The position peaked at $536K in Q3 2018. 197 funds tracked by Wall St. Rank hold SGMO as of Q4 2018.

  • R.H. Bluestein & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2018 after selling out during the quarter.
  • R.H. Bluestein & Co sold 31,600 SANGAMO THERAPEUTICS INC shares in Q4 2018, an estimated $536K.
  • R.H. Bluestein & Co first reported a position in SANGAMO THERAPEUTICS INC in Q3 2018 and held it in 1 quarter.
  • R.H. Bluestein & Co's SANGAMO THERAPEUTICS INC position peaked at $536K in Q3 2018.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2018.

Based on R.H. Bluestein & Co's 13F filing for Q4 2018, filed 13 Feb 2019.